In 759 randomised asymptomatic men aged 49-69, contrast-free MRI-first screening vs PSA-first detected more clinically significant prostate cancer (4.6% vs 1.8%; RR 2.6, p=0.05), with more biopsies (10.8% vs 5.2%); no serious adverse events.
RCTn = 759
Messina et al. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA)